Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Regtivex
- Development stage
- Unknown
- Lead developer
- Medical University of Vienna
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
Regtivex is an investigational, Treg-selective interleukin-2 (IL-2) therapy developed by researchers at the Medical University of Vienna. It is engineered as a mutein or fusion protein designed to selectively activate and expand regulatory T cells (Tregs) by preferentially targeting the high-affinity trimeric IL-2 receptor (composed of CD25, CD122, and CD132) over the dimeric receptor found on effector T cells and natural killer cells. This selective expansion of Tregs is intended to restore immune balance and induce immune tolerance, primarily to prevent organ rejection in kidney transplantation and to treat various autoimmune and immune-mediated diseases. By promoting Treg-mediated suppression, Regtivex aims to provide a more targeted therapeutic approach compared to conventional, non-specific immunosuppressants.
- Brand names
- Regtivex
- Other names
- RegTivexTreg-selective IL-2
02
Targets
IL2RG (Interleukin-2 receptor gamma subunit)IL2RB (IL-2 receptor beta chain)IL2RA (Interleukin-2 receptor alpha subunit)
Beyond the preview
Go deeper on Regtivex.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Regtivex.